Tech Company Financing Transactions
Kedalion Therapeutics Funding Round
On 8/7/2018, Kedalion Therapeutics received $5 million in Series A investment from Lagunita BioSciences and private investors.
Transaction Overview
Company Name
Announced On
8/7/2018
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series A
Investors
Lagunita BioSciences (Lead Investor) (Mark Blumenkranz)
Proceeds Purpose
Proceeds from the financing will be used to further develop the Company's technology platform through to pilot-scale GMP manufacturing and support advancement of the Company's clinical programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1490 O'Brien Dr. C
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
Kedalion's AcuStream technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Blumenkranz
Chief Financial Officer
Mark Murray
Chief Technical Officer
Ehud Ivri
VP - Operations
Casey Dougan
VP - R & D
Reynaldo Quintana
Browse more venture capital transactions:
Prev: 8/7/2018: Portion venture capital transaction
Next: 8/7/2018: CubeWorks venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to record tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs